These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 33451350)

  • 41. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
    Mortaz E; Bassir A; Dalil Roofchayee N; Dezfuli NK; Jamaati H; Tabarsi P; Moniri A; Rezaei M; Mehrian P; Varahram M; Marjani M; Mumby S; Adcock IM
    Int Immunopharmacol; 2021 Apr; 93():107407. PubMed ID: 33631512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gender differences in treatment of Coronavirus Disease-2019.
    Ambrosino I; Barbagelata E; Corbi G; Ciarambino T; Politi C; Moretti AM
    Monaldi Arch Chest Dis; 2020 Dec; 90(4):. PubMed ID: 33305554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
    Marra F; Smolders EJ; El-Sherif O; Boyle A; Davidson K; Sommerville AJ; Marzolini C; Siccardi M; Burger D; Gibbons S; Khoo S; Back D
    Drugs R D; 2021 Mar; 21(1):9-27. PubMed ID: 33336316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
    Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry.
    Keestra SM; Rodgers F; Lenz D; Osborne R; Bruckner T; Lee S
    Trials; 2021 Jun; 22(1):375. PubMed ID: 34074329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
    A Malhani A; A Enani M; Saheb Sharif-Askari F; R Alghareeb M; T Bin-Brikan R; A AlShahrani S; Halwani R; Tleyjeh IM
    PLoS One; 2021; 16(6):e0252984. PubMed ID: 34111191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advance of promising targets and agents against COVID-19 in China.
    Duan Y; Zhu HL; Zhou C
    Drug Discov Today; 2020 May; 25(5):810-812. PubMed ID: 32198066
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
    Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
    Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
    Hassaniazad M; Farshidi H; Gharibzadeh A; Bazram A; Khalili E; Noormandi A; Fathalipour M
    J Med Virol; 2022 Jul; 94(7):3184-3191. PubMed ID: 35292989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 54. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
    Yadav AK; Wen S; Xu X; Yu L
    Ann Palliat Med; 2021 Jan; 10(1):707-720. PubMed ID: 33440983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities.
    Mainoli B; Machado T; Duarte GS; Prada L; Gonçalves N; Ferreira JJ; Costa J
    BMC Med Res Methodol; 2021 Feb; 21(1):42. PubMed ID: 33637044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs.
    Shi J; Xiao Y; Zhang Y; Geng D; Cong D; Shi KX; Knapp RJ
    Br J Clin Pharmacol; 2021 May; 87(5):2170-2185. PubMed ID: 33119136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.
    Hariyanto TI; Kristine E; Jillian Hardi C; Kurniawan A
    Infect Disord Drug Targets; 2021; 21(5):e270421187364. PubMed ID: 33121422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
    Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
    Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.